Clinical Trial: HBV Reactivation in Immunocompromised Patients (REANT STUDY)

U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529171) titled 'HBV Reactivation in Immunocompromised Patients (REANT STUDY)' on April 04.

Brief Summary: Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy. For patients with anti-HBc IgG positivity requiring Hepatitis B virus (HBV) prophylaxis, the long-term physiological impact of oral antivirals remains a concern. This study aims to prospectively monitor bone, renal, and metabolic dysfunctions associated with oral antiviral use and other systemic risk factors over a long-term period.

Methods: The REANT Cohort is designed as a 4-year, multicenter prospective stu...